This digital resource summarises the key efficacy and safety data from the ECHELON-2 study,3 which investigated ADCETRIS + CHP vs CHOP in adult patients with previously untreated sALCL.
Please note, this is to be viewed online only. Not to be downloaded or printed.
If you would like to discuss this content with a Takeda representative, please click here.
CHP, cyclophosphamide, doxorubicin and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; sALCL, systemic anaplastic large cell lymphoma.
1. NICE. Brentuximab vedotin in combination for untreated sALCL [TA641]. Available at: www.nice.org.uk/guidance/ta641. Accessed September 2024; 2. SMC. Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) for adult patients with previously untreated systemic anaplastic large cell lymphoma. Available at: www.scottishmedicines.org.uk/medicines-advice/brentuximab-vedotin-adcetris-full-smc2310/. Accessed September 2024; 3. Horwitz S, et al. Lancet 2019;393:229-40.
